Tolerogenic antigen-presenting cells
Tolerogenic antigen-presenting cells (APCs) are attractive agents for the treatment of autoimmune and inflammatory diseases that are mediated, at least in part, by antigen-specific autoreactive T cells. Transforming growth factor-β (TGF-β)-treated antigen-presenting cells induce a very potent form of tolerance in mice. One unique feature of this simple and elegant method of tolerance induction is that it is equally potent in both primed and naïve mice, an important consideration for the development of a therapy that will be effective against an established disease. In this model, F4/80 peritoneal exudate cells (macrophages) cultured with antigen and TGF-β2 injected iv induce populations of regulatory T cells that mediate long-lasting antigen-specific tolerance in mice. The mechanisms that are involved in the induction of tolerance by TGF-β-treated APCs are very complex and require the interaction of a variety of cell types, as well as soluble and membrane-bound factors. In this review, we summarize the existing data and present new data concerning the induction and effector mechanisms associated with TGF-β-treated APC-induced tolerance. An understanding of these mechanisms will provide very important information for the design of effective strategies for the treatment of a variety of diseases that are mediated by pathogenic T cells.
Key WordsTolerance Tolerogenic APC TGF-β Regulatory T cells FasL Autoimmune disease
Unable to display preview. Download preview PDF.
- 16.Okano Y, Hara Y, Yao Y, Tano Y: In vitro-ACAID induction by culturing blood monocytes with transforming growth factor-beta, in Proceedings of the 6th International Symposium on the Immunology and Immunopathology of the Eye. Nussenblatt SM, Caspi RR, Gery I, eds. Elsevier Science B. V. Bethesda, MD, 1994, pp. 199–202.Google Scholar
- 28.Yehualaeshet T, O'Connor R, Green-Johnson J, Mai S, Silverstein R, Murphy-Ullrich JE, Khalil N: Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36. Am J Pathol 1999;155:841–851.PubMedGoogle Scholar
- 37.Inobe J-I, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL: IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 1998;28: 2780–2790.PubMedCrossRefGoogle Scholar
- 46.Okamoto S, Kosiewicz MM, Caspi RR, Streilein JW: ACAID as a potential therapy for established experimental autoimmune uveitis, in Advances in Ocular Immunology, Nussenblatt RB, Whitcup SM, Caspi RR, Gery I, eds. Elsevier Science B. V., Amsterdam, 1994, pp. 195–198.Google Scholar